PRESS RELEASES & ARTICLES
STAY UPDATED

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

October 04, 2017

Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

PDF

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®

September 28, 2017

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.

PDF

Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections

September 07, 2017

Allecra’s novel b-lactamase inhibitor AAI101, co-administered with the powerful b-lactam cefepime, is to be evaluated in patients for its potential to combat hospital-acquired, resistant Gram-negative infections

PDF

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

August 22, 2017
PDF

EMBL Ventures portfolio company Luxendo acquired by Bruker

May 08, 2017
PDF

Arsanis Completes $45.5 Million Series D Financing

April 26, 2017
PDF

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

April 04, 2017
PDF

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

April 04, 2017
PDF

Arsanis and Adimab Enter Into License Agreement

February 27, 2017
PDF

Arsanis Announces First Patient Dosed in Global Phase 2 Study

January 24, 2017
PDF

Crescendo partners with Genedata

January 10, 2017
PDF

Luxendo announces Series A extension

January 09, 2017
PDF

Opsona announces preliminary MDS results

December 20, 2016
PDF

Opsona receives orphan designation

October 25, 2016
PDF

Crescendo enters a collaboration with Takeda

October 10, 2016
PDF

ViraT enters collaboration with Boehringer Ingelheim

September 28, 2016
PDF

Crescendo strengthens IP portfolio

September 27, 2016
PDF

Topas Series A Financing

March 22, 2016
PDF
© EMBL Ventures 2017